La chaîne d'options affiche les données clés des options sur actions de Gevo à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Gevo..

Gevo (NASDAQ:GEVO) Stock, Chaîne d'Options

GEVO INC

Gevo

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.

Gevo Inc

During the last three months, 4 analysts shared their evaluations of Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Gevo and provided 12-month price targets. The average target is $10.79, accompanied by a high estimate of $14.00 and a low estimate of $1.15. Observing a downward trend, the current average is 4.6% lower than the prior average price target of $11.31. 
<img src="https://www.benzinga.com/files/images/story/2025/1748606459_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Gevo by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.15</td>
<td>$3.25</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gevo. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Gevo compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Gevo's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Gevo's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GEVO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gevo analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Gevo</h2>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
<h3>Gevo's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Gevo's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 629.55% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: Gevo's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -74.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Gevo's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -4.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Gevo's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -3.44%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Gevo's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.36.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GEVO

Expert Outlook: Gevo Through The Eyes Of 4 Analysts

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

News

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Gevo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported on Wednesday that it has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45642976/gevo-to-sell-luverne-minnesota-ethanol-facility-to-a-e-innovation-will-retain-isobutanol-assets-fo" rel="noreferrer noopener">agreed to sell</a> its ethanol subsidiary, Agri-Energy LLC, to A.E. Innovation LLC for $7 million. The deal includes Gevo&#8217;s idle 18-million-gallon-per-year ethanol plant in Luverne, Minnesota, which has been offline since 2022.
Gevo will retain key isobutanol assets and a portion of the site for future use, enabling the potential production of up to 1 million gallons annually of isobutanol, convertible into specialty chemicals or renewable jet fuel.
A.E. Innovation, a Minnesota-based agriculture group, plans to restart ethanol production and develop the location into a hub for scaling clean fuel technologies.
Also Read: <a href="https://www.benzinga.com/top-stories/25/05/45381191/first-solar-eyes-best-2-day-rally-since-2013-after-gop-tax-plan-spares-key-clean-energy-credits">First Solar Eyes Best 2-Day Rally Since 2013 After GOP Tax Plan Spares Key Clean Energy Credits</a>
The sale provides Gevo with $2 million upfront and $5 million in future payments while reducing approximately $3 million in annual idling costs.
Gevo CEO Patrick Gruber emphasized the opportunity to build new partnerships and highlighted Minnesota&#8217;s leadership in sustainable agriculture.
The restart of ethanol production is expected to benefit Luverne&#8217;s local economy, bolster support for farmers, and reinforce the town&#8217;s role in the renewable energy transition.
Gevo announced yesterday the <a href="https://www.benzinga.com/pressreleases/25/05/g45629960/gevo-promotes-leke-agiri-to-chief-financial-officer" target="_blank" rel="noreferrer noopener">appointment</a> of Oluwagbemileke (Leke) Agiri as Chief Financial Officer, effective May 21, 2025.  He succeeds L. Lynn Smull, who will take on a new role as Executive Vice President and Senior Advisor to the CEO.
The leadership change reflects Gevo&#8217;s long-term succession planning and positions the company for its next phase of strategic growth.
Related ETFs: Invesco WilderHill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>), First Trust NASDAQ Clean Edge Green Energy Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCLN#NASDAQ">QCLN</a>).
Price Action: GEVO shares are trading higher by 1.32% to $1.15 at last check Wednesday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45429266/solar-security-alert-communication-devices-discovered-in-chinese-inverters-heres-the-stocks-that-could-be-affected">DOE Warns Of Hidden Risks As Chinese Devices In Power Inverters Sparks National Security Concerns: 7 Stocks That Could Be In Focus</a></li>
</ul>
Image via Shutterstock

Asset Sales

Movers

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

First Trust NASDAQ Clean Edge Green Energy Index Fund

QCLN

Gevo's Ethanol Plant Sale Cuts $3 Million From Annual Expenses

Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is pleased to announce that it has entered into a definitive agreement to sell Agri-Energy, LLC ("Agri"), a wholly owned subsidiary of Gevo, to A.E. Innovation, LLC ("A.E.") for $7 million. The transaction includes Agri's 18-million-gallon-per-year ethanol-production facility located in Luverne, Minnesota. Gevo will retain ownership of certain isobutanol-production-related assets and a portion of the vacant land at the site for future use. With these retained assets, Gevo could potentially produce up to 1 million gallons per year of isobutanol, which can be sold as a specialty chemical, or converted into isooctane and jet fuel.
A.E., an agriculture-oriented buyer group located in Minnesota, will acquire the ethanol plant and a portion of the land with the intent to restart ethanol production, which has been idled since 2022. A.E. also intends to make the site available for other companies to scale up new technologies and ideas as an innovation hub.

Gevo Announces Sale Of Agri-Energy Subsidiary And 18-Million-Gallon Ethanol Plant In Luverne, Minnesota To A.E. Innovation For $7M, Retains Isobutanol Assets With Potential For Specialty Fuel Production

Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>), is pleased to announce the appointment of Oluwagbemileke (Leke) Agiri as Chief Financial Officer, effective as of May 21, 2025. Mr. Agiri succeeds L. Lynn Smull, who will continue with the Company in a new role as Executive Vice President and Senior Advisor to the Chief Executive Officer, focusing on strategic initiatives and to aide and support a seamless transition.

Management

Gevo Promotes Oluwagbemileke (Leke) Agiri As Chief Financial Officer, Effective As Of May 21, 2025

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 12.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $29.11 million which beat the analyst consensus estimate of $19.49 million by 49.35 percent. This is a 629.55 percent increase over sales of $3.99 million the same period last year.

Earnings

Earnings Beats

Gevo Q1 EPS $(0.09), Inline, Sales $29.11M Beat $19.49M Estimate

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Gevo to report an earnings per share (EPS) of $-0.08.
Investors in Gevo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 9.92% drop in the share price the following trading session.

<img src="https://www.benzinga.com/files/images/story/2025/1747076657_0.png" alt="eps graph" />
<h3>Performance of Gevo Shares</h3>
Shares of Gevo were trading at $1.16 as of May 09. Over the last 52-week period, shares are up 61.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Gevo</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Gevo.
A total of 3 analyst ratings have been received for Gevo, with the consensus rating being Buy. The average one-year price target stands at $9.72, suggesting a potential 737.93% upside.
<h3>Comparing Ratings with Competitors</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Green Plains, Clean Energy Fuels and REX American Resources, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Green Plains, with an average 1-year price target of $7.3, suggesting a potential 529.31% upside.</li>
<li>Analysts currently favor an Buy trajectory for Clean Energy Fuels, with an average 1-year price target of $4.33, suggesting a potential 273.28% upside.</li>
<li>Analysts currently favor an Buy trajectory for REX American Resources, with an average 1-year price target of $50.0, suggesting a potential 4210.34% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Green Plains, Clean Energy Fuels and REX American Resources, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gevo</td>
<td>Buy</td>
<td>30.32%</td>
<td>$2.25M</td>
<td>-3.54%</td>
</tr>
<tr>
<td>Green Plains</td>
<td>Neutral</td>
<td>-18.02%</td>
<td>$6.15M</td>
<td>-6.14%</td>
</tr>
<tr>
<td>Clean Energy Fuels</td>
<td>Buy</td>
<td>2.31%</td>
<td>$23.57M</td>
<td>-4.19%</td>
</tr>
<tr>
<td>REX American Resources</td>
<td>Buy</td>
<td>-15.66%</td>
<td>$17.57M</td>
<td>1.97%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Gevo is positioned at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, Gevo's performance is strong in terms of revenue and profit growth, but it lags behind in generating returns for its equity holders.
<h3>Get to Know Gevo Better</h3>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
<h3>Financial Insights: Gevo</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Gevo's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 30.32% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -308.89%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Gevo's ROE stands out, surpassing industry averages. With an impressive ROE of -3.54%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Gevo's ROA stands out, surpassing industry averages. With an impressive ROA of -2.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.14, Gevo adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/GEVO/earnings">To track all earnings releases for Gevo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Gevo's Quarterly Earnings

Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) announced Wednesday that it has <a href="https://www.benzinga.com/pressreleases/25/04/g44710157/gevo-and-future-energy-global-sign-saf-scope-1-and-scope-3-voluntary-carbon-credit-offtake-agreeme" target="_blank" rel="noreferrer noopener">entered a multi-year offtake agreement</a> with Future Energy Global (FEG) to supply carbon abatement credits tied to 10 million gallons per year of sustainable aviation fuel (SAF).
The agreement enables airlines and corporations to reduce their Scope 1 and Scope 3 emissions. The deal includes an option for FEG to increase the offtake volume in the future.
The deal is expected to support Gevo's financing of its ATJ-60 production facility in Lake Preston, South Dakota. Backed by a $1.63 billion conditional loan guarantee from the U.S. Department of Energy and equity from project-level investors, the plant is designed to produce 60 million gallons of low-emission SAF annually at a cost comparable to conventional jet fuel.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/guidance/25/02/43442930/gevo-buys-ethanol-ccs-assets-secures-additional-100-million-potential-funding-for-net-zero-north-expansion" rel="noreferrer noopener">Gevo Buys Ethanol &amp; CCS Assets, Secures Additional $100 Million Potential Funding For Net-Zero North Expansion</a>
With global aviation targeting net-zero emissions by 2050—and SAF projected to deliver two-thirds of the required reductions—production must scale over 400-fold. FEG addresses this challenge by offering SAF-derived Scope 1 and Scope 3 credits to buyers who can't access physical fuel, using a "Book and Claim" model that separates environmental attributes from fuel logistics to reduce costs and emissions.
Gevo CEO Dr. Patrick Gruber emphasized that a functional Book and Claim market can help unlock faster SAF adoption, including for aircraft lessors who own nearly half the global commercial fleet.
By commercializing SAF-related carbon credits and offering predictable pricing, FEG's business model helps bridge financing gaps, enabling suppliers like Gevo to expand more rapidly. While its initial focus is aviation, FEG's credit solutions extend to the marine and land transport sectors.
Price Action: GEVO shares are trading lower by 0.98% at $1.01 at the last check Wednesday.
Photo: Shutterstock

Gevo Seals SAF Offtake With FEG, Backed By DOE Loan And Net-Zero Industry Momentum

Gevo Signs SAF Scope 1 And Scope 3 Voluntary Carbon Credit Offtake Agreement With Future Energy Global

Gevo's Verity Partners With Minnesota Soybean Processors To Track And Verify Sustainable Agriculture Attributes

Throughout the last three months, 4 analysts have evaluated Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.79, a high estimate of $14.00, and a low estimate of $1.15. A decline of 4.6% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631272_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Gevo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.15</td>
<td>$3.25</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gevo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gevo compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Gevo's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gevo's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GEVO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gevo analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Gevo Better</h2>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment, Renewable Natural Gas Segment, and the Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure.
<h3>Key Indicators: Gevo's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Gevo displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 30.32%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Gevo's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -308.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.54%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Gevo's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: Gevo's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBS analyst Manav Gupta maintains Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Neutral and lowers the price target from $3.25 to $1.15.

UBS Maintains Neutral on Gevo, Lowers Price Target to $1.15

WIIM

Gevo shares are trading lower after the company reported a Q4 EPS miss.

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is unchanged from the same period last year.

Earnings Misses

Gevo Q4 2024 GAAP EPS $(0.08) Misses $(0.07) Estimate

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPG

ADCT

BCAB

BITF

BKYI

The Beachbody Company, Inc. Class A Common Stock

BODI

BRFH

BRTX

BRZE

BTTR

BZAI

CLSD

CODX

DPRO

DRCT

EDAP

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FORA

FTLF

GOVX

ICCM

INMB

IPHA

JFIN

KULR

LTRN

LULU

LVLU

PDSB

PIII

PLSE

PSTV

RLMD

SACH

SCWO

SDST

SKYH

SPRO

SSKN

TLSI

TSAT

TSSI

UMAC

UONE

UONEK

VTSI

WKSP

Earnings Scheduled For March 27, 2025

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) will release its quarterly earnings report on Thursday, 2025-03-27. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Gevo to report an earnings per share (EPS) of $-0.09.
Investors in Gevo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.02, leading to a 16.32% drop in the share price the following trading session.
Here's a look at Gevo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.09</td>
<td>-0.07</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.09</td>
<td>-0.09</td>
<td>-0.08</td>
<td>-0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-16.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743015787_0.png" alt="eps graph" />
<h3>Tracking Gevo's Stock Performance</h3>
Shares of Gevo were trading at $1.25 as of March 25. Over the last 52-week period, shares are up 60.66%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on Gevo</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Gevo.
A total of 2 analyst ratings have been received for Gevo, with the consensus rating being Buy. The average one-year price target stands at $14.0, suggesting a potential 1020.0% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Green Plains, Clean Energy Fuels and Par Pacific Hldgs, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Neutral trajectory for Green Plains, with an average 1-year price target of $8.25, indicating a potential 560.0% upside.</li>
<li>Analysts currently favor an Buy trajectory for Clean Energy Fuels, with an average 1-year price target of $4.0, suggesting a potential 220.0% upside.</li>
<li>As per analysts' assessments, Par Pacific Hldgs is favoring an Outperform trajectory, with an average 1-year price target of $22.0, suggesting a potential 1660.0% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Green Plains, Clean Energy Fuels and Par Pacific Hldgs, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gevo</td>
<td>Buy</td>
<td>-56.60%</td>
<td>$-579K</td>
<td>-4.12%</td>
</tr>
<tr>
<td>Green Plains</td>
<td>Neutral</td>
<td>-18.02%</td>
<td>$6.15M</td>
<td>-6.14%</td>
</tr>
<tr>
<td>Clean Energy Fuels</td>
<td>Buy</td>
<td>2.31%</td>
<td>$23.57M</td>
<td>-4.19%</td>
</tr>
<tr>
<td>Par Pacific Hldgs</td>
<td>Outperform</td>
<td>-16.09%</td>
<td>$119.04M</td>
<td>-4.56%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Gevo is at the bottom for Revenue Growth and Gross Profit, with negative values. It is also at the bottom for Return on Equity, with a negative percentage. Gevo's Consensus rating is 'Buy', which is in line with one other peer. Overall, Gevo ranks lower compared to its peers in terms of financial performance metrics.
<h3>Discovering Gevo: A Closer Look</h3>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment, Renewable Natural Gas Segment, and the Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure.
<h3>Unraveling the Financial Story of Gevo</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Gevo's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -56.6% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1076.64%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Gevo's ROE stands out, surpassing industry averages. With an impressive ROE of -4.12%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.46%, the company showcases effective utilization of assets.
Debt Management: Gevo's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/GEVO/earnings">To track all earnings releases for Gevo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Gevo's Earnings

<a href="https://www.axios.com/pro/climate-deals/newsletters/2025/03/25/climate-800m-spv">https://www.axios.com/pro/climate-deals/newsletters/2025/03/25/climate-800m-spv</a>
&nbsp;
Renewable fuels producer Gevo is preparing to raise about $800 million in a special purpose vehicle to build a production plant in South Dakota. Why it matters: The company will raise the funds from infrastructure firms, strategic backers and impact investors.

Financing

'Gevo To Raise $800M In Biofuels SPV' - Axios

Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) announced today that it will host its rescheduled conference call on March 27, 2025, at 4:30 p.m. ET (2:30 p.m. MT) to report its financial results for the fourth quarter ended December 31, 2024.
To participate in the live call, please register through the following event weblink:&nbsp;&nbsp; <a href="https://www.globenewswire.com/Tracker?data=LosSaMa6P0qgzY4GHUaug-JKN0uf_N6EuIUjxlbqpUrIt7vezwevK2x6tWDk8U39Fsl3ZjNeldHpcvN6-20rp1XWyI-HEACwGddVFv5Qx7OyHv15X8EKDK8OWfmvNX-CHLg6edmFX4eW8UL3TpBGFLwtX0YqYmkqAXk4tYcwKeJ2d_GnE1upClAJQGd01Suvgj-GfmdR0i_n-YLerIadoKY0-tncdO6HDSnbiWuCZ0Q=">https://register.vevent.com/register/BIfe02700a31384d12946e60bf35964cb8</a>&nbsp;
After registering, participants will be provided with a dial-in number and pin.

Events

Gevo Reschedules Conference Call On March 27, 2025, At 4:30 p.m. ET To Report Its Financial Results For Q4

Press Releases

Gevo Reports Fourth Quarter 2024 Financial Results and Reaffirms Business Update

Gevo to Participate in Virtual Investor Meeting

Verity Announces Agreement with Minnesota Soybean Processors to Track and Verify Sustainable Agriculture Attributes

General

Gevo and Future Energy Global Sign SAF Scope 1 and Scope 3 Voluntary Carbon Credit Offtake Agreement to Accelerate Book-and-Claim Market

Gevo to Report First Quarter 2025 Financial Results on May 13, 2025

Gevo Reports First Quarter 2025 Financial Results

Biotech

Gevo Promotes Leke Agiri to Chief Financial Officer

Gevo Appoints Industry Veteran James Barber, Ph.D. to Board of Directors

Contracts

Gevo to Sell Luverne, Minnesota Ethanol Facility to A.E. Innovation; Will Retain Isobutanol Assets for Future Innovation

Gevo Promotes Lindsay Fitzgerald to Chief Advocacy and Communications Officer

Aemetis

Calumet

Clean Energy Fuels

Comments

Gevo

Gevo (GEVO) Options

Gevo (NASDAQ:GEVO) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL